This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES Europe: Oligonucleotide and Peptide Therapeutics
12 - 14 Nov 2024
Hamburg Congress CentreHamburg, Germany

Nanologica

Profile

Nanologica is a Swedish nanotechnology company developing nanoporous silica for purification by chromatography.

NLAB Saga®, Nanologica’s silica-based product line, has been specifically designed for the purification of peptide drugs, such as insulin and GLP-1 analogues. NLAB Saga® has been tested and used by pharmaceutical companies worldwide manufacturing APIs at industrial scale where quality, performance and durability are uncompromisable.

Nanologica has full control of the entire manufacturing process. The company’s proprietary production method allows for precise control of the shape, size, porosity, and surface properties of silica particles leading to an optimized combination of pore volume, high surface area and high carbon load.

This results in a robust and reliable product that can streamline production processes and reduce costs for peptide drug manufacturers. This in turn can increase the availability of cost-effective medicines and give more people around the world access to vital treatments for diabetes and obesity.